Humatrope ® (somatropin)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Humatrope Summary of Product Characteristics (SmPC)

Humatrope® (somatropin): Interaction with other medicinal products

Humatrope (somatropin) may interact with other medicines

Patients with diabetes mellitus who receive concomitant somatropin may require adjustment of their doses of insulin and/or other anti-hyperglycaemic agents.

Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth. Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective.

In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal.

Somatropin can increase cytochrome P450 (CYP) enzyme activity in humans and may result in reduced plasma concentrations and decreased effectiveness of drugs metabolised by CYP3A such as sex steroids, corticosteroids, cyclosporine and anticonvulsants.

Reference

Humatrope Summary of Product Characteristics

Date of Last Review: April 05, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question